Stay informed with the latest litigation news. Explore now

IP Verse

Cambridge Enterprise patent opposition analysis

Latest patents of Cambridge Enterprise New

Explore the latest patents granted to Cambridge Enterprise, showcasing their recent innovations and technological advancements.

Last updated on: Aug 31, 2025

Patent Number	Grant Date	Title	Legal Status
Get instant update for new patents of Cambridge Enterprise
EP3166628	Jul 26, 2023	Therapeutic Use Of Bone Morphogenetic Proteins	Patent Maintained As Amended
EP3545079	Apr 6, 2022	Controllable Transcription	Granted And Under Opposition
EP3183336	Nov 25, 2020	Resetting Pluripotent Stem Cells	Granted And Under Opposition
EP2564467	Oct 28, 2020	Rfid Tag Interrogation Systems	Patent Maintained As Amended
EP2825646	Aug 7, 2019	Methods For Obtaining Liquid From A Solid Phase	Revoked
EP2364480	Mar 7, 2018	Substance Monitoring And Control In Human Or Animal Bodies	Granted And Under Opposition
EP2470060	Jan 10, 2018	Visual Perimeter Measurement System And Method	No Opposition Filed Within Time Limit
EP2621647	Jan 3, 2018	Spin Forming Process And Apparatus For Manufacturing Articles By Spin Forming	No Opposition Filed Within Time Limit

Latest patents of Cambridge Enterprise opposed by its competitors

Explore Cambridge Enterprise's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 4, 2025

Patent Number	Grant Date	Title	Total Oppositions
EP3166628	Jul 26, 2023	Therapeutic Use Of Bone Morphogenetic Proteins	1
EP3545079	Apr 6, 2022	Controllable Transcription	1
EP3183336	Nov 25, 2020	Resetting Pluripotent Stem Cells	1
EP2564467	Oct 28, 2020	Rfid Tag Interrogation Systems	1
EP2825646	Aug 7, 2019	Methods For Obtaining Liquid From A Solid Phase	1
EP2364480	Mar 7, 2018	Substance Monitoring And Control In Human Or Animal Bodies	1

Top competitors of Cambridge Enterprise

Top competitors of Cambridge Enterprise based on patent oppositions.

JAMES POOLE

KRAUS & LEDERER PARTGMBB

MILTENYI